BACKGROUND T-cell lymphomas (T-NHL) generally carry a poor prognosis. High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) are increasingly used to treat younger patients. DESIGN AND METHODS We treated patients <61 years with high-risk aggressive lymphoma with four to six courses of dose-escalated CHOP plus etoposide (MegaCHOEP) necessitating repeated ASCT. Outcomes of pati...

Bendamustine (Treanda, Cephalon) is a unique compound composed of an alkylating agent (a nitrogen mustard derivate) and a benzimidazole ring (similar to a purine analog).1 Originally developed in the 1960s, the rationale behind the drug was to use both its antimetabolite activity and alkylating properties to produce an effective drug with a lower toxicity profile than other alkylating agents.2 ...

INTRODUCTION Radiation therapy is an important component of curative therapy for Lymphoma [Hodgkin's disease (HD) and non Hodgkin's Lymphoma (NHL)]. The current study was conducted to give us an overview of lymphoma patients presenting to a tertiary care hospital for complementary adjuvant RT. METHOD Data of lymphoma patients who underwent radiotherapy during February 2006 till August 2009 at...

Few studies of reproductive hormone exposures and non-Hodgkin lymphoma (NHL) have examined NHL subtypes. Associations between reproductive hormonal factors and risk of all NHL and of two predominant subtypes, diffuse large-cell lymphoma (DLCL) (n = 233) and follicular lymphoma (n = 173), were investigated among women (n = 581) in a large, population-based, case-control study (1,591 cases, 2,515...

PURPOSE Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action. This phase II multicenter study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab. PATIENTS AND METHODS Patients received bendamustine 120 mg/m(2) intravenously on days 1 and 2 of each 21-day cycle. Outcomes included response...

OBJECTIVE To determine survival rates of patients with lymphoma in South Australia. DESIGN AND SETTING De-identified data from the SA Cancer Registry on all patients with lymphoma were analysed, as well as the subgroup treated at the Royal Adelaide Hospital (RAH). For non-Hodgkin lymphoma (NHL), we used the International Working Formulation (IWF) grading. SA and RAH data on survival rates wer...

Rituximab (Rituxan) is a genetically engineered chimeric murine/human monoclonal antibody and the first monoclonal antibody to become available to physicians for the treatment of malignant disease. It has recently been licensed for use in the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive B-cell Non-Hodgkins Lymphoma (NHL). Its mechanism of action is by...

The etiology of non-Hodgkin lymphoma (NHL) is poorly understood. Obesity is associated with inflammation, a cytokine milieu conducive to lymphocyte proliferation, and has been associated with NHL risk in some epidemiologic studies. To prospectively examine NHL risk in relation to adult and earlier life obesity, we documented 635 incident NHL diagnoses among 46,390 men in the Health Professional...

It is rare for systemic non-Hodgkin's lymphoma (NHL) to metastasize to the hypothalamus and pituitary glands. The present study describes two patients with NHL and diabetes insipidus (DI) and 17 patients from the literature in order to analyze the clinical features of patients with NHL metastasizing to the pituitary glands. Diffuse large B cell lymphoma (DLBCL) was observed to be the most commo...

objective(s): the aim of this study is to evaluate the role of pet-ct in identification of different patterns of extranodal involvement in hodgkin’s disease (hd) and non-hodgkin’s lymphoma (nhl) and to enlist the common sites of extranodal involvement in each histological type and compare our results with the existing literature. methods: in this retrospective study of 281 cases of lymphomas of...